Association of Pre- and Posttreatment Neutrophil-Lymphocyte Ratio With Recurrence and Mortality in Locally Advanced Non-Small Cell Lung Cancer

• Published in: Frontiers in oncology Vol. 10; p. 598873
• Main Authors: Sebastian, Nikhil T, Raj, Rohit, Prasad, Rahul, Barney, Christian, Brownstein, Jeremy, Grecula, John, Haglund, Karl, Xu-Welliver, Meng, Williams, Terence M, Bazan, Jose G
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 05-11-2020
• Subjects: chemoradiation; locally advanced; neutrophil–lymphocyte ratio; non-small cell lung cancer; Oncology; vertebral body; non-small cell lung cancer; locally advanced; neutrophil–lymphocyte ratio; chemoradiation; vertebral body
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.598873

Neutrophil-lymphocyte ratio (NLR) has been associated with mortality in non-small cell lung cancer (NSCLC), but its association with recurrence in locally advanced NSCLC (LA-NSCLC), specifically, is less established. We hypothesized pre- and posttreatment NLR would be associated with recurrence and mortality.
We studied the association of pretreatment NLR (pre-NLR) and posttreatment NLR at 1 (post-NLR
) and 3 months (post-NLR
) with outcomes in patients with LA-NSCLC treated with chemoradiation. Pre-NLR was dichotomized by 5, an
cutoff previously shown to be prognostic in LA-NSCLC. Post-NLR
and post-NLR
were dichotomized by their medians.
We identified 135 patients treated with chemoradiation for LA-NSCLC between 2007 and 2016. Median follow-up for living patients was 61.1 months. On multivariable analysis, pre-NLR ≥ 5 was associated with worse overall survival (HR = 1.82; 95% CI 1.15 - 2.88; p = 0.011), but not with any recurrence, locoregional recurrence, or distant recurrence. Post-NLR
≥ 6.3 was not associated with recurrence or survival. Post-NLR
≥ 6.6 was associated with worse overall survival (HR = 3.27; 95% CI 2.01- 5.31; p < 0.001), any recurrence (HR = 2.50; 95% CI 1.53 - 4.08; p < 0.001), locoregional recurrence (HR = 2.50; 95% CI 1.40 - 4.46; p = 0.002), and distant recurrence (HR = 2.53; 95% CI 1.49 - 4.30; p < 0.001).
Pretreatment NLR is associated with worse overall survival and posttreatment NLR is associated with worse survival and recurrence. These findings should be validated independently and prospectively studied.